UniProtKB/Swiss-Prot P68871: Variant p.Lys9Gln

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 9 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LB/B The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Lysine (K) to Glutamine (Q) at position 9 (K9Q, p.Lys9Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from large size and basic (K) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Polymorphism: Genetic variations in HBB are involved in resistance to malaria [MIM:611162]. Hemoglobin S (Hb S), which at homozygosity is responsible for sickle cell anemia, is not associated with any clinical abnormality when heterozygous. At heterozygosity, Hb S confers an increase in protection from life-threatening malaria. Additional variants conferring resistance against severe malaria are hemoglobin C (Hb C) and hemoglobin E (Hb E). Additional information on the polymorphism described.
Variant description: In J-Luhe. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs33926764 [ dbSNP | Ensembl ]

Sequence information

Variant position: 9 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 147 The length of the canonical sequence.
Location on the sequence: MVHLTPEE K SAVTALWGKVNVDEVGGEAL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Initiator methionine	1 – 1	Removed
Chain	2 – 147	Hemoglobin subunit beta
Domain	3 – 147	Globin
Binding site	2 – 2
Binding site	3 – 3
Site	8 – 9	(Microbial infection) Cleavage; by N.americanus apr-2
Modified residue	2 – 2	N-acetylvaline
Modified residue	2 – 2	N-pyruvate 2-iminyl-valine; in Hb A1b
Modified residue	10 – 10	Phosphoserine
Modified residue	13 – 13	Phosphothreonine
Glycosylation	2 – 2	N-linked (Glc) (glycation) valine; in Hb A1c
Glycosylation	9 – 9	N-linked (Glc) (glycation) lysine
Glycosylation	18 – 18	N-linked (Glc) (glycation) lysine
Helix	6 – 17

Literature citations

Hemoglobin Istanbul: substitution of glutamine for histidine in a proximal histidine (F8(92)).
Aksoy M.; Erdem S.; Efremov G.D.; Wilson J.B.; Huisman T.H.J.; Schroeder W.A.; Shelton J.R.; Shelton J.B.; Ulitin O.N.; Muftuoglu A.;
J. Clin. Invest. 51:2380-2387(1972)
Cited for: VARIANT ISTAMBUL GLN-93;